Biogen to Present Aducanumab Phase 3 Topline Results at Clinical Trials on Alzheimer’s Disease (CTAD) Congress on December 5, 2019
Zurich, Switzerland
-
04.12.2019
Biogen announced it will host live webcasts of the presentation and a Q&A session related to aducanumab at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) annual congress in San Diego, California.
Thursday, December 5, 2019: 11:00 a.m. ET – Aducanumab Phase 3 topline results
Thursday, December 5, 2019: 5:00 p.m. ET – Investor Q&A call.
This website uses cookies, with the aim of ensuring that you have the best possible online experience. In using our website, you are giving your consent to the terms and conditions of our Privacy policy
Your web browser is out of date
Update your browser for more security, speed and the best experience.
